Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed133%
withdrawn133%
active_not_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
completedphase_1

Combination Study of SV-BR-1-GM With Retifanlimab

NCT03328026
active_not_recruitingphase_1

Personalized DC Vaccines in Non Small Cell Lung Cancer

NCT05195619
withdrawnphase_1

PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma

NCT05714306

Clinical Trials (3)

Showing 3 of 3 trials
NCT03328026Phase 1

Combination Study of SV-BR-1-GM With Retifanlimab

Completed
NCT05195619Phase 1

Personalized DC Vaccines in Non Small Cell Lung Cancer

Active Not Recruiting
NCT05714306Phase 1

PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3